Background: Esophageal adenocarcinoma (EA) and gastric cardia adenocarcinoma (GCA) are characterized by a strong male predominance. Concentrations of sex steroid hormones have been hypothesized to explain this sex disparity. However, no prospective population-based study has examined sex steroid hormones in relation to EA/GCA risk. Thus, we investigated whether prediagnostic circulating sex steroid hormone concentrations were associated with EA/GCA in a nested case-control study drawn from participants in three prospective cohort studies. Methods: Using gas chromatography-mass spectrometry (GC-MS) and electrochemiluminescence immunoassay, we quantitated sex steroid hormones and sex hormone binding globulin, respectively, in serum from 259 EA/GCA male case participants and 259 matched male control participants from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, and Cancer Prevention Study II Nutrition Cohort. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between circulating hormones and EA/GCA risk. All statistical tests were two-sided. Results: Higher concentrations of dehydroepiandrosterone (DHEA) were associated with a 38% decreased risk of EA/GCA (OR per unit increase in log2 DHEA = 0.62, 95% CI = 0.47 to 0.82, Ptrend = .001). Higher estradiol concentrations were associated with a 34% reduced risk of EA/GCA (OR = 0.66, 95% CI = 0.45 to 0.98, Ptrend = .05), and the association with free estradiol was similar. No other associations between baseline hormone concentrations and future EA/GCA risk were observed. Conclusions: This study provides the first evidence that higher concentrations of circulating DHEA, estradiol, and free estradiol may be associated with lower risks of EA/GCA in men.
Background: Esophageal adenocarcinoma (EA) and gastric cardia adenocarcinoma (GCA) are characterized by a strong male predominance. Concentrations of sex steroid hormones have been hypothesized to explain this sex disparity. However, no prospective population-based study has examined sex steroid hormones in relation to EA/GCA risk. Thus, we investigated whether prediagnostic circulating sex steroid hormone concentrations were associated with EA/GCA in a nested case-control study drawn from participants in three prospective cohort studies. Methods: Using gas chromatography-mass spectrometry (GC-MS) and electrochemiluminescence immunoassay, we quantitated sex steroid hormones and sex hormone binding globulin, respectively, in serum from 259 EA/GCA male case participants and 259 matched male control participants from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, Alpha-Tocopherol, Beta-CaroteneCancer Prevention Study, and Cancer Prevention Study II Nutrition Cohort. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between circulating hormones and EA/GCA risk. All statistical tests were two-sided. Results: Higher concentrations of dehydroepiandrosterone (DHEA) were associated with a 38% decreased risk of EA/GCA (OR per unit increase in log2 DHEA = 0.62, 95% CI = 0.47 to 0.82, Ptrend = .001). Higher estradiol concentrations were associated with a 34% reduced risk of EA/GCA (OR = 0.66, 95% CI = 0.45 to 0.98, Ptrend = .05), and the association with free estradiol was similar. No other associations between baseline hormone concentrations and future EA/GCA risk were observed. Conclusions: This study provides the first evidence that higher concentrations of circulating DHEA, estradiol, and free estradiol may be associated with lower risks of EA/GCA in men.
Authors: R B Hayes; D Reding; W Kopp; A F Subar; N Bhat; N Rothman; N Caporaso; R G Ziegler; C C Johnson; J L Weissfeld; R N Hoover; P Hartge; C Palace; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: Majon Muller; Isolde den Tonkelaar; Jos H H Thijssen; Diederick E Grobbee; Yvonne T van der Schouw Journal: Eur J Endocrinol Date: 2003-12 Impact factor: 6.664
Authors: Alina Maria Mehedinţeanu; Cecil Sorin Mirea; Puiu Olivian Stovicek; Michael Schenker; Marius Ionuţ Stancu; Ana Maria Ciurea; Liliana Streba; Anca Maria Istrate-Ofiţeru; Teodor Nicuşor Sas; Cristin Constantin Vere Journal: Rom J Morphol Embryol Date: 2021 Oct-Dec Impact factor: 0.833
Authors: Shao-Hua Xie; Rui Fang; Mingtao Huang; Juncheng Dai; Aaron P Thrift; Lesley A Anderson; Wong-Ho Chow; Leslie Bernstein; Marilie D Gammon; Harvey A Risch; Nicholas J Shaheen; Brian J Reid; Anna H Wu; Prasad G Iyer; Geoffrey Liu; Douglas A Corley; David C Whiteman; Carlos Caldas; Paul D Pharoah; Laura J Hardie; Rebecca C Fitzgerald; Hongbing Shen; Thomas L Vaughan; Jesper Lagergren Journal: Clin Gastroenterol Hepatol Date: 2019-11-19 Impact factor: 11.382
Authors: Zhikai Zhu; Yingxi Chen; Jiansong Ren; Sanford M Dawsey; Jian Yin; Neal D Freedman; Jin-Hu Fan; Philip R Taylor; Yuanli Liu; You-Lin Qiao; Christian C Abnet Journal: Cancer Prev Res (Phila) Date: 2021-03-25
Authors: Úna C McMenamin; Peipei Liu; Andrew T Kunzmann; Michael B Cook; Helen G Coleman; Brian T Johnston; Marie M Cantwell; Chris R Cardwell Journal: Am J Gastroenterol Date: 2021-03-01 Impact factor: 12.045